Literature DB >> 22765848

Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids.

Annette L van Ojik1, Paul A F Jansen, Jacobus R B J Brouwers, Eric N van Roon.   

Abstract

In the treatment of chronic malignant and non-malignant pain, opioids are used as strong analgesics. Frail elderly patients often have multiple co-morbidities and use multiple medicines, leading to an increased risk of clinically relevant drug-drug and drug-disease interactions. Age-related changes and increased frailty may lead to a less predictable drug response, increased drug sensitivity, and potential harmful drug effects. As a result, physicians face a complex task in prescribing medication to elderly patients. In this review, the appropriateness of the strong-acting opioids buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone and tapentadol is determined for use in elderly patients. Evidence-based recommendations for prescribing strong opioids to the frail elderly are presented. A literature search was performed for all individual drugs, using a validated and published set of 23 criteria concerning effectiveness, safety, pharmacokinetics and pharmacodynamics, experience, and convenience in elderly patients. First, information on the criteria was obtained from pharmaceutical reference books and a MEDLINE search. The information obtained on the individual drugs in the class of opioids was compared with the reference drug morphine. Evidence-based recommendations were formulated on the basis of the pros and cons for the frail elderly. Using the set of 23 criteria, no differentiation can be made between the appropriateness of buprenorphine, fentanyl, hydromorphone, morphine and oxycodone for use in elderly patients. Methadone has strong negative considerations in the treatment of chronic pain in the frail elderly. Methadone has a high drug-drug interaction potential and is associated with prolongation of the QT interval and a potential risk of accumulation due to a long elimination half-life. In addition, methadone is difficult to titrate because of its large inter-individual variability in pharmacokinetics, particularly in the frail elderly. Because of a lack of empiric knowledge, the use of tapentadol is not recommended in frail elderly persons. Nevertheless, tapentadol may prove to be a useful analgesic for the treatment of chronic pain in frail elderly persons because of its possible better gastrointestinal tolerability. In the treatment of chronic pain in the frail elderly, the opioids of first choice are buprenorphine, fentanyl, hydromorphone, morphine and oxycodone. In order to improve the convenience for elderly patients, the controlled-release oral dosage forms and transdermal formulations are preferred.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22765848     DOI: 10.2165/11632620-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  48 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Drug therapy in the elderly.

Authors:  Klaus Turnheim
Journal:  Exp Gerontol       Date:  2004 Nov-Dec       Impact factor: 4.032

Review 3.  Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment.

Authors:  Andrew J McLachlan; Sally Bath; Vasi Naganathan; Sarah N Hilmer; David G Le Couteur; Stephen J Gibson; Fiona M Blyth
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 4.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine.

Authors:  M H Beers; J G Ouslander; I Rollingher; D B Reuben; J Brooks; J C Beck
Journal:  Arch Intern Med       Date:  1991-09

5.  Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors:  S Ahmedzai; D Brooks
Journal:  J Pain Symptom Manage       Date:  1997-05       Impact factor: 3.612

6.  Opioid dose and drug-related mortality in patients with nonmalignant pain.

Authors:  Tara Gomes; Muhammad M Mamdani; Irfan A Dhalla; J Michael Paterson; David N Juurlink
Journal:  Arch Intern Med       Date:  2011-04-11

7.  Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone.

Authors:  I Maddocks; A Somogyi; F Abbott; P Hayball; D Parker
Journal:  J Pain Symptom Manage       Date:  1996-09       Impact factor: 3.612

8.  Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.

Authors:  A J Clark; S H Ahmedzai; L G Allan; F Camacho; G L A Horbay; U Richarz; K Simpson
Journal:  Curr Med Res Opin       Date:  2004-09       Impact factor: 2.580

9.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

10.  Management of expected and unexpected opioid-related side effects.

Authors:  Juan-Diego Harris
Journal:  Clin J Pain       Date:  2008-05       Impact factor: 3.442

View more
  18 in total

1.  Comment on "Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?".

Authors:  Olfat Zekry; Charles A Inderjeeth
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

2.  Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids.

Authors:  Joseph V Pergolizzi
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

3.  What analgesics do older people use prior to initiating oxycodone for non-cancer pain? A retrospective database study.

Authors:  Svetla Gadzhanova; J Simon Bell; Elizabeth E Roughead
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

4.  The Elderly Spine Surgery Patient: Pre- and Intraoperative Management of Drug Therapy.

Authors:  Jess W Brallier; Stacie Deiner
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

Review 5.  Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?

Authors:  Felicity C Veal; Gregory M Peterson
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

Review 6.  Emerging Challenges to the Safe and Effective Use of Methadone for Cancer-Related Pain in Paediatric and Adult Patient Populations.

Authors:  Kyle P Edmonds; Ila M Saunders; Andrew Willeford; Toluwalase A Ajayi; Rabia S Atayee
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

Review 7.  A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly.

Authors:  Beatriz Gras-Miralles; Filippo Cremonini
Journal:  Clin Interv Aging       Date:  2013-02-15       Impact factor: 4.458

8.  A Nationwide Retrospective Study of Opioid Management Patterns in 2,468 Patients with Spinal Pain in Korea.

Authors:  Sung-Soo Chung; Chun-Kun Park; Kyu-Jung Cho; Kyoung Hyo Choi; Jin-Hyok Kim; Sung-Bum Kim; Sung-Uk Kuh; Jae Chul Lee; Jae Hyup Lee; Kyu-Yeol Lee; Sun-Ho Lee; Seong-Hwan Moon; Si-Young Park; Jae Hang Shim; Byung-Chul Son; Myung Ha Yoon; Hye-Jeong Park
Journal:  Asian Spine J       Date:  2016-12-08

Review 9.  Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain.

Authors:  Tracy L Skaer
Journal:  J Pain Res       Date:  2014-08-19       Impact factor: 3.133

Review 10.  Pharmacotherapy of Pain in the Older Population: The Place of Opioids.

Authors:  Milica Prostran; Katarina Savić Vujović; Sonja Vučković; Branislava Medić; Dragana Srebro; Nevena Divac; Radan Stojanović; Aleksandar Vujović; Lepa Jovanović; Ana Jotić; Nataša Cerovac
Journal:  Front Aging Neurosci       Date:  2016-06-16       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.